Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from finnish and swedish patients with psoriasis

Acta Dermato-Venereologica

Volumn 91, Issue 4, 2011, Pages 409-414

  Hjortsberg, Catharina ^a   Bergman, Annika ^a   Bjarnason, Anton ^b   Heikkilä, Hannele ^c   Hjelmgren, Jonas ^d   Svensson, Åke ^c   Tennvall, Gunnel Ragnarson ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Janssen Cilag AB   (Sweden)

Author keywords

Disease severity; HRQoL; Patient registries; Patient satisfaction; Psoriasis

Indexed keywords

CORTICOSTEROID DERIVATIVE; EMOLLIENT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DISEASE MARKER; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FINLAND; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SELF EVALUATION; SWEDEN;

ADULT; AGED; COST OF ILLNESS; DIAGNOSTIC SELF EVALUATION; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958810124     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1094     Document Type: Article

References (26)

1. SBU Alert. [New immunomodulating drugs in treating moderate to severe psoriasis]. SBU Alert 2006: 1-11 (in Swedish).
2. Psoriasisliitto-Psoriasisförbundet 2009. [Facts about psoriasis]. Available from: http://www.psori.f/.
3. de Korte J, Sprangers M, Mombers F, Bos J. Quality of life in patients with psoriasis: a systematic literature review. J Invest Dermatol 2004; 9: 140-147.
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
5. Fortune D, Richards H, Griffths C. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005; 23: 681-694.
6. Eghlileb A, Davies EE, Finlay A. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245-1250.
7. Schmitt J, Ford D. Work limitations and productivity loss are associated with Health-Related Quality of Life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-110.
8. Naldi L, Svensson A, Zenoni D, Diepgen T, Elsner P, Grob J-J, et al. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. Br J Dermatol 2010; 162: 384-389.
9. Rich S. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. J Manag Care Pharm 2004; 10: 38-41.
10. Leonardi C, Kimball A, Papp K. Efficacy and safety of uste-kinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
11. Menter A, Feldman S, Weinstein G, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infiximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e31-e15.
12. Saurat J-H, Stingl G, Dubertret L, Papp K, Langley R, Ortonne J, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007; 158: 558-566.
13. Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213: 327-330.
14. Stern R, Nijsten T, Feldman S, Margolis D, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-139.
15. Dubertret L, Mrowietz U, Ranki A, kerkhof PCM, Chimenti S, Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736.
16. LFN. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. Stockholm: The Pharmaceutical Benefits Board (LFNAR 2003: 2). Available from: http://www.tlv.se.
17. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Economics 1996; 5: 141-154.
18. Finlay A, Khan G. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
19. Shikiar R, Bresnahan B, Stone S, Thompson C, Koo J, Revicki D. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
20. Wahl A, Loge J, Wiklund I, Hanestad B. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000; 43: 803-808.
21. Hongbo Y, Thomas C, Harrison M, Salek M, Finlay A. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: 659-664.
22. Schmitt-Egenolf M. [PsoReg, the Swedish registry for systemic psoriasis treatment. Annual report September 2007-August 2008]. PsoReg, Umeå Universitet 2008 (in Swedish).
23. Flytström I, Stenberg B, Svensson Å, Bergbrant I-M. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2007; 158: 116-121.
24. Nyberg F, Osika I, Evengård B. The laundry bag project" - unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol 2008; 47: 144-149.
25. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007; 5: 209-218.
26. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 5: 566-574.